Centessa Pharmaceuticals (CNTA) Other Gross PP&E Adjustments (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Other Gross PP&E Adjustments of -$12.2 million for Q1 2026, down 12.78% year-over-year from -$14.0 million in Q1 2025, and down 27.9% on a QoQ basis from -$9.6 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$12.2 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments fell 12.78% year-over-year to -$12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.2 million (down 12.78% YoY) and the FY2025 annual result came in at -$9.6 million, up 15.07% from the prior year.
- Other Gross PP&E Adjustments eased to -$12.2 million in Q1 2026 per CNTA's latest filing, from -$9.6 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.3 million in Q2 2022 and bottomed at -$13.9 million in Q1 2023.
- The 5-year median for Other Gross PP&E Adjustments is -$10.8 million (2025), against an average of -$9.2 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments surged 59.25%; it then sank 877.34% in 2023.
- Tracing CNTA's Other Gross PP&E Adjustments over 5 years: stood at -$2.8 million in 2022, then plunged by 304.54% to -$11.5 million in 2023, then increased by 1.96% to -$11.3 million in 2024, then advanced by 15.07% to -$9.6 million in 2025, then dropped by 27.9% to -$12.2 million in 2026.
- Per Business Quant, the three latest CNTA Other Gross PP&E Adjustments figures stand at -$12.2 million (Q1 2026), -$9.6 million (Q4 2025), and -$9.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | -12.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.23 Mn |
| Mar 31, 2026 | -12.23 Mn |
| Dec 31, 2025 | -9.56 Mn |
| Dec 31, 2025 | -9.56 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Jun 30, 2025 | -10.83 Mn |
| Jun 30, 2025 | -10.83 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Mar 31, 2025 | -10.85 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Dec 31, 2024 | -11.26 Mn |
| Sep 30, 2024 | -10.72 Mn |
| Sep 30, 2024 | -10.72 Mn |
| Jun 30, 2024 | -11.10 Mn |
| Jun 30, 2024 | -11.10 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Dec 31, 2023 | -11.49 Mn |
| Dec 31, 2023 | -11.49 Mn |
| Sep 30, 2023 | -12.38 Mn |
| Sep 30, 2023 | -12.38 Mn |
| Jun 30, 2023 | -13.03 Mn |
| Jun 30, 2023 | -13.03 Mn |
| Mar 31, 2023 | -13.93 Mn |
| Mar 31, 2023 | -13.93 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.33 Mn |
| Jun 30, 2022 | -1.33 Mn |
| Mar 31, 2022 | -1.95 Mn |
| Mar 31, 2022 | -1.95 Mn |
| Dec 31, 2021 | -1.32 Mn |
| Dec 31, 2021 | -1.32 Mn |
| Sep 30, 2021 | -2.32 Mn |
| Sep 30, 2021 | -2.32 Mn |
| Jun 30, 2021 | -3.27 Mn |
| Jun 30, 2021 | -3.27 Mn |
| Dec 31, 2020 | -37,000.00 |
| Dec 31, 2020 | -37,000.00 |